Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10224
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoberts, Matthew A-
dc.contributor.authorHare, David L-
dc.contributor.authorRatnaike, Sujiva-
dc.contributor.authorIerino, Francesco L-
dc.date.accessioned2015-05-15T23:36:22Z
dc.date.available2015-05-15T23:36:22Z
dc.date.issued2006-09-01en
dc.identifier.citationAmerican Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation; 48(3): 341-60en
dc.identifier.govdoc16931208en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10224en
dc.description.abstractCardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with all forms of chronic kidney disease (CKD). The underlying pathological state is caused by a complex interplay of traditional and nontraditional risk factors that results in atherosclerosis, arteriosclerosis, and altered cardiac morphological characteristics. This multifactorial disease introduces new challenges in predicting and treating patients with CVD sufficiently early in the course of CKD to positively alter patient outcome. Asymptomatic individuals with progressive CVD are a group of patients that deserve focused attention because early detection and intervention may provide the best opportunity for improved outcome. However, identifying CVD in asymptomatic patients with CKD or end-stage renal disease remains a significant hurdle in the management of these patients. Recently, a number of cardiovascular biomarkers were identified as predictors of patient outcome in individuals with CVD and, with additional research, may be used to guide the early diagnosis of and therapy for CVD in patients with CKD. This review examines the pathophysiological characteristics and potential clinical role of these novel cardiovascular biomarkers in risk stratification, risk monitoring, and selection of preventive therapies for patients with CKD.en
dc.language.isoenen
dc.subject.otherBiological Markers.analysisen
dc.subject.otherBone Marrow.physiologyen
dc.subject.otherCardiovascular Diseases.etiology.physiopathology.therapyen
dc.subject.otherChronic Diseaseen
dc.subject.otherGlycosylationen
dc.subject.otherHumansen
dc.subject.otherInflammationen
dc.subject.otherKidney Diseases.complicationsen
dc.subject.otherKidney Transplantationen
dc.subject.otherMyocardium.pathologyen
dc.subject.otherNecrosisen
dc.subject.otherOxidative Stressen
dc.subject.otherPlatelet Activationen
dc.subject.otherProteins.metabolismen
dc.subject.otherRisk Assessmenten
dc.subject.otherVentricular Function, Leften
dc.titleCardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleAmerican journal of kidney diseases : the official journal of the National Kidney Foundationen
dc.identifier.affiliationDepartment of Nephrology, Division of Laboratory Medicine, Austin Health, University of Melbourne, Victoria, Australiaen
dc.identifier.doi10.1053/j.ajkd.2006.06.005en
dc.description.pages341-60en
dc.identifier.orcid0000-0001-9554-6556-
dc.identifier.pubmedid16931208-
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptCardiology-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.